28th July 2026
Advocating for access to Libmeldy
Alex TLC recently submitted evidence for the Scottish Medicine Consortium review of the medicine Libmeldy for approval of it through NHS Scotland for patients with metachromatic leukodystrophy (MLD).
Helping to cope, helping to hope
Established in 2004, Alex TLC provides invaluable support and information to people affected by leukodystrophy.
Formerly ALD Life, for people affected by adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN), we extended our services to support all leukodystrophies in 2019 and became Alex, The Leukodystrophy Charity.
There are more than 100 different known types of leukodystrophy, including some so rare they only affect one or two individuals. We are the only charity in the UK that provides support and information to people affected by any of the leukodystrophy conditions worldwide.
Leukodystrophies are genetic disorders primarily affecting the white matter of the central nervous system (ie. the brain or spinal cord). The majority of leukodystrophies are degenerative, causing symptoms such as impaired mobility, vision, speech and hearing, incontinence, inability to swallow and loss of cognitive skills. In some cases, they may be life limiting. These conditions affect males and females of all ages and ethnic backgrounds, most notably children.
Have you or a family member been diagnosed with a leukodystrophy?
We understand the information you have received may be new and confusing, and it may be difficult to know where to go for further advice and information.
You can help us to raise vital funds and increase awareness of leukodystrophies.
The majority of people aren’t aware of these rare diseases and their impact on individuals and their families. With your help, however small, we can make a real difference.
These pages are packed full of ideas and inspiration for the various ways you and/or your organisation can get involved and lend your support.
Discover how you can get involved today.
We are constantly updating our news section with everything of interest to people affected by leukodystrophies. You will find information about our latest work, health and research news, updates for professionals, and more.
28th July 2026
Alex TLC recently submitted evidence for the Scottish Medicine Consortium review of the medicine Libmeldy for approval of it through NHS Scotland for patients with metachromatic leukodystrophy (MLD).
27th July 2026
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male cALD patients
27th July 2026
We have been fighting to add adrenoleukodystrophy (ALD) to the UK Newborn Screening Blood Spot Programme since 2017 and submitted extensive additional evidence to the National Screening Committee (NSC) this month.
24th July 2026
Alex TLC has been working closely with Genetic Alliance as part of their Future for Rare campaign to inform what future UK rare disease policy should look like.
20th July 2026
Rare Summit 2026 is going to be a hybrid event – giving you the flexibility to join us from around the world.
20th July 2026
We’re pleased to share Genetic Alliance UK’s research report, Independent Evaluation of the Generation Study: Views of support organisations.